Home
Acceleron Pharma

Acceleron Pharma Market Share Analysis for May 2026

Merck's online newsroom offers real-time news about Merck's prescription medicines, vaccines and consumer care products.

Health > Biotechnology and Pharmaceuticals

Domainacceleronpharma.com

Year Founded2003

Employees201 - 500

Annual Revenue$100M - $200M

Acceleron Pharma

Acceleron Pharma (including company regionals)

acceleronpharma.com

See more website traffic and engagement information

Acceleron Pharma Revenue up to May 2026 is 100M - 200M

revenue generated by Acceleron Pharma top domains

Acceleron Pharma top domains revenue over 3 years

Revenue for Acceleron Pharma top domains

acceleronpharma.com100M - 200M

See more with Sales Intelligence

Total visits to Acceleron Pharma's top domains

Understand Acceleron Pharma market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Acceleron Pharma's top domains

Analyze Acceleron Pharma engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Acceleron Pharma's top domains

See how Acceleron Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Acceleron Pharma top competitors by domain

Top similar sites in May 2026, ranked by their affinity

cambrex.comCompany NameCambrexEmployees1001 - 5000HQUnited States, New Jersey, East RutherfordAnnual revenue$500M - $1BTotal visits34.9KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Acceleron Pharma

These are the website technologies, by industry, used by Acceleron Pharma top domains

Audio Video Media (3)

VideoJS

Advertising (2)

DoubleClick

Content Management System (2)

WordPress

Conversion & Analytics (2)

Google Analytics

More Technologies

7

See all

News & Signals from Acceleron Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMerck Manuals, Inc acquired Acceleron Pharma Inc. for $11.5B on Jan 1st '21.In 2021, Merck paid $11.5 billion to acquire Acceleron Pharma and its pulmonary arterial hypertension (PAH) drug sotatercept.

NewsMerck Sharp & Dohme Corp. acquired Acceleron Pharma Inc. for $11.5B on Jan 1st '21.MSD acquired exclusive rights to sotatercept in the pulmonary hypertension field through the acquisition of Acceleron Pharma Inc.

NewsAcceleron Pharma Inc. launches drug in the first-line setting for MDS.Reblozyl has already achieved more than satisfactory sales since its launch, and as per DelveInsight's analysis, we estimate this drug to be a blockbuster therapy at its peak year considering the fact that BMS and Acceleron Pharma have also planned to launch the drug in the first-line setting for MDS after a final data readout in the year by late 2022.